Abstract
We assessed long-term outcome in 155 patients who had undergone an allogeneic/syngeneic stem cell transplant (SCT) and were in complete remission for more than 2 years after transplant. Probability of late transplant-related mortality was 6%, and affected only patients with chronic graft-versus-host disease (cGVHD). Thirteen percent of patients experienced relapse. Overall survival projected at 10 and 15 years was 83% and 76%, respectively. Secondary malignancies occurred in two patients, 7.5 and 11 years after SCT. Three female and four male patients parented children 19 to 84 months after SCT. Quality of life (QoL) was assessed in a cross-sectional study by the means of a 30-item questionnaire (QLQ-C30) of the EORTC. The questionnaire was sent to 127 patients remaining alive and answered by 106 patients. Seventy-three percent reported a good to very good QoL within 5 years after SCT and 78% after this time point. However, patients with cGVHD had significant impairment of physical, role and social functioning and only 60% of them were fit for work. These results from long-term survivors show that high cure rates with good to very good QoL can be achieved by allogeneic or syngeneic SCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
O'Donnell MR, Nademanee AP, Snyder DS et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes J Clin Oncol 1987 5: 1822 1826
Gahrton G, Tura S, Ljungman P et al. Allogeneic bone marrow transplantation in multiple myeloma New Engl J Med 1991 325: 1267 1273
Clift RA, Appelbaum FR, Thomas ED . Treatment of chronic myeloid leukemia by bone marrow transplantation Blood 1993 82: 1954 1956
Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia New Engl J Med 1995 332: 217 223
Passweg JR, Socié G, Hinterberger W et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood 1997 90: 858 864
de Witte T, Hermans J, Vossen J et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukemias: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Br J Haematol 2000 110: 620 630
Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion Ann Intern Med 1988 108: 806 814
Appelbaum FR . The influence of total dose, fractionation, dose rate, and distribution of total body irradiation on bone marrow transplantation Semin Oncol 1993 20: (Suppl. 4) 3 10
Tutschka PJ . Use of busulfan containing chemotherapy for conditioning patients with leukemia for bone marrow allografting Bone Marrow Transplant 1993 12: (Suppl. 1) 34 36
Boeckh M, Bowden RA, Gooley T et al. Successful modification of a pp65 antigenemia based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients Blood 1999 93: 1781 1782
Roy V, Ochs L, Weisdorf D . Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis Leuk Lymphoma 1997 26: 1 15
Winston DJ, Gale RP . Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s Bone Marrow Transplant 1991 8: 7 11
Fischer GF, Faé I, Petrasek M, Moser S . A combination of two distinct in vitro amplification procedures for DNA typing of HLA-DRB and -DQB1 alleles Vox Sang 1995 69: 328 335
Greinix HT, Volc-Platzer B, Knobler RM . Extracorporeal photochemotherapy in the treatment of severe graft-versus-host disease Leuk Lymphoma 2000 36: 425 434
Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for acute leukemia New Engl J Med 1986 314: 729 735
Frassoni F, Labopin M, Gluckman E et al. Are patients with acute leukemia, alive and well 2 years post bone marrow transplantation cured? A European survey Leukemia 1994 8: 924 928
Singhal S, Powles R, Treleaven J et al. Long-term outcome of adult acute leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from an HLA-identical sibling Leuk Lymphoma 1999 34: 287 294
Deeg HJ, Socié G, Schoch G et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients Blood 1996 87: 386 392
Curtis RE, Rowlings PA, Deeg HJ et al. Solid cancers after bone marrow transplantation New Engl J Med 1997 336: 897 904
Sutherland HJ, Fyles GM, Adams G et al. Quality of life following bone marrow transplantation: a comparison of patient reports with population norms Bone Marrow Transplant 1997 19: 1129 1136
Hjermstad MJ, Holte H, Evensen SA et al. Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year? Bone Marrow Transplant 1999 24: 911 918
Chiodi S, Spinelli S, Ravera G et al. Quality of life in 244 recipients of allogeneic bone marrow transplantation Br J Haematol 2000 110: 614 619
Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation New Engl J Med 1975 292: 832 843 895 902
Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression Blood 1981 57: 267 276
Sullivan KM, Witherspoon RP, Storb R et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease Blood 1988 72: 555 561
Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 1993 85: 365 376
Bush NE, Haberman M, Donaldson G, Sullivan KM . Quality of life of 125 adults surviving 6–8 years after bone marrow transplantation Soc Sci Med 1995 40: 479 490
Rabitsch W, Deviatko E, Keil F et al. Successful lung transplantation for bronchiolitis obliterans after allogeneic marrow transplantation Transplantation 2001 71: 1341 1343
Gmeinhart B, Hinterberger W, Greinix HT et al. Anaplastic squamous cell carcinoma (SCC) in a patient with chronic cutaneous graft-versus-host disease (GVHD) Bone Marrow Transplant 1999 11: 1197 1199
Reiter E, Greinix HT, Keil F et al. Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia Ann Hematol 1999 78: 507 513
Hinterberger-Fischer M, Kier P, Kalhs P et al. Fertility, pregnancies and offspring complications after bone marrow transplantation Bone Marrow Transplant 1991 7: 5 9
Witherspoon R, Flournoy N, Thomas ED et al. Recurrence of acute leukemia more than two years after allogeneic marrow grafting Exp Hematol 1986 14: 178 181
Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients Blood 1996 86: 2041 2050
Sanders JE, Hawley J, Levy W et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation Blood 1996 87: 3045 3052
Syrjala KL, Chapko MK, Vitaliano PP et al. Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning Bone Marrow Transplant 1993 11: 319 327
Andrykowski MA, Brady MJ, Greiner CB et al. ‘Returning to normal’ following bone marrow transplantation: outcomes, expectations and informed consent Bone Marrow Transplant 1995 15: 573 581
Duell T, Van Lint MT, Ljungman P et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT working party on late effects and EULEP study group on late effects. European group for blood and marrow transplantation Ann Intern Med 1997 126: 184 192
Acknowledgements
We thank the nurses, fellows and house staff and the medical technicians of our stem cell transplant program, Department of Blood Group Serology and Transfusion Medicine and Department for Radiotherapy and the physicians who referred patients to our unit.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Worel, N., Biener, D., Kalhs, P. et al. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant 30, 619–626 (2002). https://doi.org/10.1038/sj.bmt.1703677
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703677
Keywords
This article is cited by
-
Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation
Radiation Oncology (2022)
-
Pretransplant Psychological Assessment for Stem Cell Treatment
Journal of Health Service Psychology (2018)
-
The effect of pre-transplant pain and chronic disease self-efficacy on quality of life domains in the year following hematopoietic stem cell transplantation
Supportive Care in Cancer (2018)
-
Temporal trajectory of quality of life and its predictors in recipients of hematopoietic stem cell transplantation
Annals of Hematology (2018)
-
Investigating the temporal course, relevance and risk factors of fatigue over 5 years: a prospective study among patients receiving allogeneic HSCT
Bone Marrow Transplantation (2017)